Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

VICTORY : The VICTORY Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18-75Age 18-75

Blood<br/>CancersCancer LocationBlood

Systemic therapy | Blood / Myeloma / LymphomaAcute Lymphoblastic Leukaemia,Acute Myeloid Leukaemia,B-Cell Non Hodgkin Lymphoma,Chronic Lymphocytic Leukaemia,Leukaemia,Lymphoma,Multiple Myeloma,Myelodysplasia

Trial Overview Read MoreRead more

This phase I study is assessing the safety and appropriate dose level of targeted therapy (venetoclax) before treatment with chemotherapy drugs (fludarabine and cyclophosphamide) in people with certain blood cancers or disorders who are planned to undergo allogenic haematopoietic stem cell transplantation.

This trial is treating patients with acute leukaemia, myelodysplastic syndrome, chronic lymphocytic leukaemia, B-cell non-Hodgkin lymphoma, and plasma cell lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

The VICTORY Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Other Non-Commercial Sponsor

Melbourne Health


Eligible participants will be enrolled sequentially into one of 4 treatment dose level cohorts to receive short-course oral venetoclax on day-11 to -6, followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day-5 to -3). Allogenic stem cell infusion will occur on day 0. in the dose-escalation phase of this 3+3 study, three participants are planned for each Dose Level. The dose-expansion phase of this study involves recruitment of up to 12 participants at the Maximum Tolerated Dose (MTD) level.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Jessica Ahern

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.